Table 2.
Estimation results from Cox proportional hazard models of mortality from all causes, HCC, and other causes in the whole cohort, adjusted for sex, education, duration of diabetes, and the presence of hepatitis and cirrhosis, as well as year of and age at HCC diagnosis and HCC stage.
| Overall Mortality | HCC Mortality | Other-Cause Mortality | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | n | HR | 95% CI | n | HR | 95% CI | n | |
| Prediagnostic metformin use | |||||||||
| Yes | 0.84 | (0.74–0.94) | 762 | 0.86 | (0.75–0.99) | 660 | 0.71 | (0.53–0.97) | 102 |
| No | 1.00 | Ref. | 448 | 1.00 | Ref. | 365 | 1.00 | Ref. | 83 |
| Prediagnostic other ADM use | |||||||||
| Yes | 0.99 | (0.88–1.11) | 664 | 0.97 | (0.85–1.11) | 558 | 1.04 | (0.76–1.42) | 106 |
| No | 1.00 | Ref. | 546 | 1.00 | Ref. | 467 | 1.00 | Ref. | 79 |
| Prediagnostic insulin use | |||||||||
| Yes | 1.00 | (0.88–1.14) | 468 | 0.99 | (0.86–1.14) | 397 | 1.09 | (0.78–1.52) | 71 |
| No | 1.00 | Ref. | 742 | 1.00 | Ref. | 628 | 1.00 | Ref. | 114 |
| Prediagnostic statin use | |||||||||
| Yes | 0.91 | (0.80–1.04) | 444 | 0.91 | (0.80–1.05) | 384 | 0.88 | (0.62–1.23) | 60 |
| No | 1.00 | Ref. | 766 | 1.00 | Ref. | 641 | 1.00 | Ref. | 125 |
ADM = antidiabetic medication, HCC = hepatocellular carcinoma, HR = hazard ratio, CI = confidence interval.